Last reviewed · How we verify
Cross-Over Boceprevir Treatment
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins.
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins. Used for Chronic hepatitis C virus (HCV) infection, genotype 1.
At a glance
| Generic name | Cross-Over Boceprevir Treatment |
|---|---|
| Also known as | SCH 503034, Victrelis |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | HCV NS3 protease inhibitor |
| Target | HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Boceprevir directly inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease, the drug prevents viral maturation and replication. The 'cross-over' designation typically refers to a trial design where patients switch between treatment regimens.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1
Common side effects
- Anemia
- Dysgeusia (taste perversion)
- Nausea
- Fatigue
- Diarrhea
- Headache
Key clinical trials
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (PHASE3)
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (PHASE2)
- Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cross-Over Boceprevir Treatment CI brief — competitive landscape report
- Cross-Over Boceprevir Treatment updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI